AD Bioinformatics and Genomics Services Companies

Overview

Overview

Bioinformatics and genomics services play a critical role in Alzheimer's disease research by providing the infrastructure for genetic analysis, biomarker discovery, and mechanistic studies. This page catalogs companies offering sequencing, single-cell genomics, multi-omics integration, and bioinformatics services relevant to AD research. The companies listed here provide the technological backbone for major discoveries in AD genetics, from the identification of [APOE](/genes/apoe) as the primary genetic risk factor to recent breakthroughs in understanding microglial biology through [TREM2](/genes/trem2) risk variants.

Major Service Providers

Illumina

• Headquarters: San Diego, CA, USA
• Website: [illumina.com](https://www.illumina.com)
• Services: Next-generation sequencing (NGS), whole genome sequencing, exome sequencing, arrays
• AD Relevance: Illumina platforms are extensively used in AD genetics consortia, including the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the International Alzheimer's Disease Genetics Consortium. Their NovaSeq and HiSeq systems enable large-scale GWAS and whole genome sequencing studies identifying AD risk genes including [APOE](/genes/apoe), [TREM2](/genes/trem2), and [CLU](/genes/clu).

The Illumina NovaSeq 6000 delivers highest-throughput sequencing at $2-5 per Gb, making it cost-effective for large AD cohort studies. The system has been used to sequence over 100,000 AD and control genomes globally, identifying rare coding variants in genes involved in [microglial immune response](/mechanisms/microglial-activation-pathway), [lysosomal function](/mechanisms/lysosomal-autophagy-pathway), and [protein homeostasis](/mechanisms/proteostasis-pathway).

The Illumina Infinium MethylationEPIC array provides genome-wide DNA methylation profiling, identifying epigenetic changes in AD brain tissue. Studies using this platform have documented hypermethylation at [TREM2](/genes/trem2) promoter regions in AD cases, correlating with reduced TREM2 expression and enhanced [neuroinflammation](/mechanisms/neuroinflammation-pathway).

Thermo Fisher Scientific

• Headquarters: Waltham, MA, USA
• Website: [thermofisher.com](https://www.thermofisher.com)
• Services: Sequencing services, gene expression analysis, proteomics, reagents
• AD Relevance: Provides the Ion Torrent platform for targeted sequencing panels used in AD research. Their TaqMan assays are the gold standard for SNP genotyping in AD genetics studies.

The Ion GeneChef S5 XL system enables rapid targeted sequencing of AD genetic panels within 24 hours. Commercial panels include genes involved in [amyloid processing](/mechanisms/amyloidogenesis-pathway) (APP, PSEN1, PSEN2), [tau phosphorylation](/mechanisms/tau-phosphorylation-pathway) (MAPT), and [autophagy-lysosomal](/mechanisms/lysosomal-autophagy-pathway) pathways (GRN, CTSH, CTSS).

TaqMan genotyping assays have been used to confirm [APOE](/genes/apoe) genotype in over 500,000 AD research subjects worldwide. The ε4 allele remains the strongest genetic risk factor for late-onset AD, increasing risk 3-4 fold in heterozygotes and 10-15 fold in homozygotes.

Pacific Biosciences

• Headquarters: Menlo Park, CA, USA
• Website: [pacb.com](https://www.pacb.com)
• Services: Long-read sequencing (HiFi), whole genome sequencing
• AD Relevance: PacBio HiFi sequencing resolves complex structural variants and repeat expansions in AD genes. Their technology has identified novel [APOE](/genes/apoe) haplotypes and rare structural variants in [TREM2](/genes/trem2) associated with increased AD risk.

PacBio HiFi sequencing achieves >99.9% accuracy with 15-25 kb read lengths, enabling resolution of complex genomic regions. This is particularly important for:

• APOE region: Long-read sequencing has identified novel [APOE](/genes/apoe) isoforms and structural variants that influence AD risk through altered lipid binding properties
• TREM2: HiFi sequencing resolves rare missense variants in [TREM2](/genes/trem2) that impair microglial phagocytosis and contribute to [amyloid accumulation](/mechanisms/amyloid-plaque-formation)
• GRN: Identifies null mutations causing frontotemporal dementia and enhancing AD risk through dysregulated progranulin signaling

Oxford Nanopore Technologies

• Headquarters: Oxford, UK
• Website: [nanoporetech.com](https://nanoporetech.com)
• Services: Long-read sequencing, portable sequencing
• AD Relevance: Nanopore sequencing enables real-time detection of methylation patterns relevant to AD epigenetics. The portable MinION device allows bedside sequencing for rapid biomarker analysis.

The MinION platform provides portable long-read sequencing (up to 4 Mb reads) with direct methylation detection. Applications in AD research include:

• Epigenetic aging: DNA methylation age acceleration correlates with AD progression and provides prognostic indicators for [cognitive decline](/mechanisms/cognitive-decline-pathway)
• 5hmC detection: hydroxymethylcytosine patterns in AD brain reveal gene-specific epigenetic dysregulation
• Real-time diagnostics: Portable sequencing enables rapid point-of-care biomarker analysis for clinical trial enrollment

10x Genomics

• Headquarters: Pleasanton, CA, USA
• Website: [10xgenomics.com](https://www.10xgenomics.com)
• Services: Single-cell genomics, spatial transcriptomics, multi-omics
• AD Relevance: 10x Chromium and Visium platforms are used to generate single-cell atlases of AD brain, identifying cell-type specific gene expression changes in [neurons](/entities/neurons), [microglia](/cell-types/microglia-neuroinflammation), and [astrocytes](/cell-types/astrocytes). Key studies include the Seattle-Alzheimer's Disease Brain Cell Atlas (SEA-AD).

The Chromium Single Cell Gene Expression platform enables transcriptomic profiling of individual cell types in AD brain:

• Microglia: Single-cell analysis identified disease-associated microglia (DAM) expressing [TREM2](/genes/trem2), [APOE](/genes/apoe), and [CLU](/genes/clu), forming an inflammatory interface between [amyloid plaques](/mechanisms/amyloid-plaque-formation) and [neurons](/entities/neurons)
• Astrocytes: Reactive astrocytes showing upregulated [GFAP](/genes/gfap) and [AQP4](/genes/aqp4) in AD brain regions with [tau pathology](/mechanisms/tau-pathology-spreading)
• Neurons: Selective vulnerability of [ excitatory neurons](/entities/excitatory-neurons) in entorhinal cortex and CA1 hippocampal regions

• Plaque-associated microenvironments: Spatial transcriptomics reveals microglial clustering around [amyloid plaques](/mechanisms/amyloid-plaque-formation) with distinct inflammatory signatures
• Neuritic plaques: Co-localization of [tau](/mechanisms/tau-pathology) and [amyloid](/mechanisms/amyloid-beta-pathway) in neuritic dystrophies
• Regional vulnerability: Molecular signatures explaining selective vulnerability of entorhinal cortex and hippocampus

NanoString Technologies

• Headquarters: Seattle, WA, USA
• Website: [nanostring.com](https://www.nanostring.com)
• Services: Spatial transcriptomics (CosMx SMI), nCounter analysis
• AD Relevance: NanoString's GeoMx DSP enables spatially resolved transcriptomics of AD brain regions, revealing region-specific molecular signatures in [hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), and [prefrontal cortex](/brain-regions/prefrontal-cortex).

The GeoMx Digital Spatial Profiler enables high-plex spatial transcriptomics with morphological context:

• Region-specific analysis: 5,000+plex gene expression in morphologically defined regions (plaque, neuritic, non-affected)
• Cell-type deconvolution: Identifies cell-type specific changes within spatial regions
• Cohort studies: Applied to >1,000 AD brain samples across multiple brain banks

• Cell segmentation: Individual cell profiling in intact tissue sections
• Multi-omic integration: Simultaneous protein and RNA measurement
• Spatial trajectories: Cell-cell interaction mapping in AD tissue

GENEWIZ (Azenta Life Sciences)

• Headquarters: South Plainfield, NJ, USA
• Website: [genewiz.com](https://www.genewiz.com)
• Services: Sanger sequencing, next-gen sequencing, synthesis, CRISPR services
• AD Relevance: Provides genomic services to AD research institutions globally, supporting GWAS validation and targeted sequencing projects.

Twist Bioscience

• Headquarters: South San Francisco, CA, USA
• Website: [twistbioscience.com](https://www.twistbioscience.com)
• Services: Gene synthesis, exome capture, target enrichment
• AD Relevance: Twist's target enrichment panels enable cost-effective sequencing of AD candidate genes. Their synthetic genes support functional studies of [APP](/genes/app), [PSEN1](/genes/psen1), and [PSEN2](/genes/psen2) mutations.

Services for AD Research

| Service Type | Companies | Application |
|------------|-----------|-------------|
| Whole Genome Sequencing | Illumina, PacBio, Nanopore, GENEWIZ | Rare variant discovery, structural variants |
| Exome Sequencing | Illumina, Thermo Fisher, Twist | Rare coding variant identification |
| Single-cell Genomics | 10x Genomics, NanoString | Cell type decomposition, trajectory analysis |
| Spatial Transcriptomics | NanoString, 10x Genomics | Region-specific molecular signatures |
| Epigenomics | Illumina, Nanopore | DNA methylation, chromatin accessibility |
| Proteomics | Thermo Fisher, Illumina | Biomarker discovery, pathway analysis |
| Bioinformatics | GENEWIZ, Illumina | Data analysis, variant interpretation |

Research Applications

Genetics and Genomics

• Large-scale GWAS identifying AD risk loci
• Whole genome sequencing for rare variant discovery
• Transcriptomics for gene expression changes
• Epigenomics for DNA methylation patterns

Biomarker Discovery

• Blood-based biomarker development
• CSF protein profiling
• Multi-omics integration for biomarker panels

Molecular Mechanisms

• Single-cell analysis of cell-type specific changes
• Spatial mapping of pathological processes
• Gene set enrichment analysis

Key Disease Links

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Early-onset Alzheimer's Disease](/diseases/early-onset-alzheimers-disease)
• [Genetics of Alzheimer's Disease](/mechanisms/genetics-alzheimers-disease)
• [APOE](/genes/apoe) — major genetic risk factor
• [TREM2](/genes/trem2) — microglial risk gene
• [Biomarkers](/biomarkers/index)

References